stockrow
Saturday 7 November 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
- EPS
- +17.7%
- Free cash flow
- −26.4%
Quarter to June 2026, against a year earlier
4.21
0.20
+4.99%
Follow ANNX
Alert me
Annexon, Inc. (ANNX) P/E ratio
Annexon, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | n/m |
| ANNX Annexon, Inc. | n/m |
| MGTX MeiraGTx Holdings PLC compare | 11.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)